Neuphoria Therapeutics Inc
NASDAQ:NEUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China Kings Resources Group Co Ltd
SSE:603505
|
CN |
|
C
|
Celebrity Fashions Ltd
NSE:CELEBRITY
|
IN |
|
X
|
Xinlong Holding Group Company Ltd
SZSE:000955
|
CN |
|
China Merchants Securities Co Ltd
SSE:600999
|
CN |
|
Guangzhou Tech-Long Packaging Machinery Co Ltd
SZSE:002209
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth $-31.18 (754% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2 | $4.77 |
0%
|
| Industry Average | 13.3 | $-31.18 |
-754%
|
| Country Average | 14.4 | $-33.66 |
-806%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
N
|
Neuphoria Therapeutics Inc
NASDAQ:NEUP
|
25.6m USD | -2 | -4.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 14.6 | 88 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.4 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.8B USD | 12.6 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD | 21.3 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 43.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 10.9 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Neuphoria Therapeutics Inc
Glance View
Neuphoria Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Burlington, Massachusetts and currently employs 8 full-time employees. Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The firm is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
